Clopidogrel is a prescription antiplatelet used after selected arterial clot-related events or procedures. Confidence in its clinical role is high; independent comparative efficacy remains uncleared here. Purpose.
- Clopidogrel, Plavix and Grepid: check the exact preparation.
- Bleeding, head injury or neurological symptoms need urgent assessment.
- Never independently stop treatment for a dental or surgical procedure.
- Omeprazole/esomeprazole, medicines and herbs: seek a pharmacist’s review.
- Pregnancy/feeding: seek individual advice; two older-infant cases cannot establish general safety.
Table of contents
- Evidence summary
- Clopidogrel names
- Platelet activation
- Uses
- Lifestyle and supplement boundaries
- Original CURE and POINT evidence
- Urgent bleeding
- PPI interactions
- Pregnancy/feeding
- Taking and procedures
- Ownership and reporting
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Clinical role | UK/US labels. | Manufacturer 4/D. | Selected licences. |
| Original outcomes | CURE/POINT originals. | Maker funding/supply, Tier 4/D. | Methods read; efficacy estimates excluded. |
| Infant evidence | Two 2025 cases; SPS context. | Industry-linked programme/commissioned service; gaps. | Cannot establish general infant safety. |
| Combination checks | NHS page. | Public route; contributor gaps. | Individual review. |
Clopidogrel names
Clopidogrel tablets reduce platelet stickiness. NHS-listed brand names include Plavix and Grepid. It is used after selected heart attacks, strokes/TIAs, unstable angina, peripheral arterial disease and coronary stenting. Uses.
England recorded 12,225,940 clopidogrel prescription items in 2025/26, BNF code 0209000C0. Original row.
PCA includes hospital-issued prescriptions dispensed in the community, not hospital dispensary supplies. Items do not count individual people, indication, benefit or worldwide prescribing. Dataset.
Platelet activation
Clopidogrel’s active metabolite blocks platelet P2Y12 receptors; it is a prodrug. Mechanism.
US boxed warning: two nonfunctional CYP2C19 alleles reduce activity; testing and alternatives require professional interpretation. Boxed warning.
Laboratory measurements and future clinical events are different outcomes. This review does not supply personal testing, dosing or switching algorithms.
Uses
UK Plavix: selected acute coronary syndromes, minor-stroke/high-risk-TIA combinations; atrial fibrillation (AF) only with additional risk, unsuitable vitamin-K antagonists, low bleeding risk, with aspirin. UK scope.
US: acute coronary syndromes with aspirin, recent heart attack/stroke or established peripheral arterial disease; AF not listed. US scope.
Never substitute for an AF anticoagulant; ask the prescriber. See Aspirin.
Lifestyle and supplement boundaries
NHS advice includes appropriate activity, balanced food, smoking cessation and alcohol review. Avoid grapefruit juice. Lifestyle/juice.
Do not add pain-relief aspirin or ibuprofen without medical agreement. Review ginkgo and St John’s wort; other supplement combinations may be uncertain. Pain/herbs.
No independently cleared supplement replacement is established in this review. Bring the actual ingredient list of fish oils, herbal blends and products marketed for circulation to the pharmacist rather than relying on a “natural” label. There is no supplement dose or brand ranking here. Lifestyle work is discussed alongside the prescribed plan, not as an automatic reason to remove one of its medicines.
Ask which activity or dietary changes fit your recovery and other conditions. A practical review should distinguish the medicine’s purpose, an interaction check and the wider prevention plan. A product advertised as helping blood flow has not thereby demonstrated the same clinical role.
Original CURE and POINT evidence
CURE compared masked, randomised clopidogrel-plus-aspirin with placebo-plus-aspirin in selected non-ST-elevation acute coronary syndromes. Its primary composite concerned cardiovascular death, heart attack or stroke. Important bleeding-risk and anticoagulant groups were excluded. Original methods.
POINT similarly randomised selected minor-ischaemic-stroke/high-risk-TIA patients, after imaging. Candidates for thrombolysis/endovascular treatment or requiring anticoagulation were excluded. It assessed an ischaemic composite and major bleeding. Original methods.
Both originals report manufacturer funding or supplied medicine: Tier 4/D. Their efficacy estimates are excluded from this independent verdict.
Randomisation, masking, academic management and public grants can improve a study’s methods without making its financial chain independent. This distinction does not show that prescribed treatment is ineffective. It explains why licensed clinical roles and sponsored outcome estimates are presented separately. A review that includes these trials cannot automatically remove their underlying conflicts; an independent comparative verdict would need eligible human trials with their own funding and interests checked.
Different events, treatment combinations, exclusions and endpoints must be kept in view when discussing evidence with a clinician. Neither a composite endpoint nor a selected trial population directly predicts an individual person’s outcome. No numerical benefit, bleeding estimate or “best antiplatelet” ranking is adopted here.
Urgent bleeding
Easier bruising/bleeding, heavier periods, diarrhoea, stomach discomfort or indigestion can occur. Persistent/bothersome symptoms need professional review. Other effects.
UK NHS 111 now/local urgent care: blood in urine, black/tarry stool or stool blood, jaundice, extreme tiredness/infection signs such as fever/sore throat, or a head injury. Drug causation remains uncertain. Urgent route.
A&E now: coughing/vomiting blood or coffee-ground vomit, unstoppable nosebleed, or severe headache with confusion, speech problems/weakness, light sensitivity or vomiting. Severe airway swelling, breathing difficulty or collapse: emergency 999/local number. Do not drive yourself. Emergency route.
Fever with pinpoint bruising, extreme tiredness, confusion or jaundice can signal thrombotic thrombocytopenic purpura: immediate medical assessment. Severe allergic skin/swelling reactions also need immediate help. TTP/allergy warning.
Acquired haemophilia requires specialist care and stopping clopidogrel if confirmed. Confirmed disorder.
Urgency overrides routine continuity advice; reporting cannot delay care.
PPI interactions
US labeling: avoid omeprazole/esomeprazole despite timing separation; avoid repaglinide combinations. Interactions.
Review anticoagulants/other antiplatelets, NSAIDs and SSRIs. These can add bleeding risk; omitting a drug from this short list does not clear it. Combination review.
The current UK generic record also addresses rifampicin/strong enzyme induction, ritonavir/cobicistat, opioids, rosuvastatin and CYP2C8-substrate interactions. Exact changes require professional advice. Current record.
Unlisted combinations need pharmacist review.
Pregnancy/feeding
Clopidogrel is not usually recommended in pregnancy, but may remain necessary. Do not stop without the doctor’s advice. Feeding decisions consider the infant and clinical need. Individual advice.
UK Plavix advises precautionary pregnancy avoidance and no breastfeeding during treatment. UK label.
US professional text requires maternal-treatment, delivery-bleeding and lactation assessment; its patient guide calls for a clinician decision to avoid/discontinue breastfeeding if continuing Plavix is needed. US label.
SPS’s dated cautious feeding advice covers healthy full-term infants, with monitoring; premature/unwell infants or multiple medicines need specialist advice. Professional scope.
Two mothers at 7–14 months postpartum provided milk for a 2025 observational study; infants had complementary food. One infant plasma sample cannot establish newborn or long-term safety. New case series.
Disclose ulcers, previous brain bleeding, recent injury/surgery, bleeding disorders, liver/kidney problems and allergies before treatment. Medical history.
UK contraindications: active pathological bleeding, severe liver impairment; review related-antiplatelet allergy. Contraindications.
Poor infant feeding, easy bruising/bleeding, diarrhoea, irritability or other concerns: contact a healthcare professional or UK 111 as soon as possible. Infant concerns.
No independent feeding/treatment changes.
Taking and procedures
Do not stop prescribed clopidogrel without medical advice; premature interruption can increase clot-related risk. Never double a missed dose. More than prescribed: UK NHS 111 immediately/local urgent advice. Taking/extra dose.
Too many Plavix tablets: contact a doctor or the nearest hospital emergency department. Pack instruction.
Tell the surgeon/dentist you take clopidogrel; never independently stop it before a procedure. Feeling well does not justify stopping. Procedure/continuity.
Milpharm tablets contain lactose; review inherited sugar disorders. Excipients.
For supply or procedures, seek advice; bring the pack without delaying care.
Useful review questions are specific: which condition is being treated, which combinations are intended, when is the plan reconsidered and who should be called about a change? Keep the actual instructions available when moving between hospital, community pharmacy and dental care.
Ownership and reporting
Sanofi reports commercial Plavix sales; current finance does not identify historic investigator payments. Seller route.
Milpharm’s filed immediate controller is Agile Pharma BV; Aurobindo’s own statement describes the intermediate group relationship. Filed control.
The Aurobindo financial list identifies Milpharm and Agile as step-down subsidiaries. Full ultimate investors and the supplied-pack factory remain unclosed. Group list.
Yellow Card collects suspected side-effect reports; reporting does not establish causation or incidence and is separate from urgent assessment. Reporting.
Animal, cell and simulated results are excluded from the human efficacy and pregnancy/infant-safety verdict. Public hosting does not make a maker’s label independent. Current corporate reports can document ownership or revenue without proving how a past trial, disease page or specific author was paid. The funding map preserves those distinctions rather than treating missing information as a clean financial chain.
Funding and source roles
Research funding at a glance
56 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS purpose | Shared DHSC website route; contributor/study interests unclosed. | United Kingdom. | Tier 2; provisional | B. March 2025 context. |
| NHS side effects | Shared DHSC website route; contributor/study interests unclosed. | United Kingdom. | Tier 2; provisional | B. March 2025 context. |
| NHS taking | Shared DHSC website route; contributor/study interests unclosed. | United Kingdom. | Tier 2; provisional | B. March 2025 context. |
| NHS pregnancy/feeding | Shared DHSC website route; contributor/study interests unclosed. | United Kingdom. | Tier 2; provisional | B. March 2025 context. |
| NHS combinations | Shared DHSC website route; contributor/study interests unclosed. | United Kingdom. | Tier 2; provisional | B. March 2025 context. |
| NHS suitability | Shared DHSC website route; contributor/study interests unclosed. | United Kingdom. | Tier 2; provisional | B. March 2025 context. |
| NHS questions | Shared DHSC website route; contributor/study interests unclosed. | United Kingdom. | Tier 2; provisional | B. March 2025 context. |
| Plavix UK SmPC | Seller finance. Sanofi’s Aventis Pharma Ltd, Reading. Pack plant unclosed. Host. | United Kingdom. | Tier 4; manufacturer | D. December 2023 text/January 2024 hosting; safety/licence. |
| Plavix PIL | Sanofi UK holder; listed manufacturer Sanofi Winthrop Industrie, Ambarès-et-Lagrave, France. Shared seller route. Host. | UK. | Tier 4; manufacturer | D. December 2022 text; January 2023 hosting. Pack plant unclosed. |
| Milpharm SmPC | Group finance. Milpharm Ltd, Stockley Park, Uxbridge holder; pack plant unclosed. Host. | United Kingdom. | Tier 4; manufacturer | D. June 10, 2026 revision; June 17 hosting. Safety, not independent efficacy. |
| US Plavix | Sanofi-Aventis US LLC, Morristown NJ; seller route; Host budget. | USA. | Tier 4; manufacturer | D. May 2025. |
| SPS antiplatelets and feeding | Commissioning. Complete bibliography/contributor interests unclosed. | United Kingdom. | Tier 2; provisional context | C. July 2023; healthy full-term infants only. Dated evidence limits. |
| CURE original, 2001 | Sanofi-Synthelabo/BMS funding. Yusuf: CIHR award/Ontario Heart & Stroke chair; Mehta: Canadian Heart & Stroke fellowship. Yusuf/Mehta/Tognoni/Fox: sponsor honoraria/consulting. | Multinational; Canadian coordination. | Tier 4; manufacturer-funded | D. Original methods/full published money read; historic ledgers unclosed. Efficacy excluded. |
| POINT original, 2018 | NINDS grants; Sanofi medicine/placebo supply and manuscript comments. Johnston/Easton/Farrant: AstraZeneca grants; Easton: Boehringer consulting; Kim: SanBio grant/Neuravi fees. | Multinational; predominantly US recruitment. | Tier 4; manufacturer-supplied | D. Replica methods/indexed original Notes read; full individual disclosure forms unclosed. Efficacy excluded. |
| 2025 milk cases | IMI2 821520: EU Horizon 2020/EFPIA; Nauwelaerts/Smits/Ceulemans FWO awards. Annaert: BioNotus co-owner. BELpREG authors: separate Sanofi pregnancy-registry grant; company uninvolved in current study. | Belgium/Netherlands/US affiliations. | Tier 4; industry-supported programme | D. Two cases; full methods/funding/COI read. Study allocation unclosed; infant safety unestablished. |
| Sanofi H1 finance, 2026 | Commercial medicine/vaccine sales, including Plavix; distribution/manufacturing-service income. Full individual page/trial allocations unclosed. | France; Paris group. | Tier 4; seller finance | D. Selected actual 66-page interim report; not a complete historical-payment ledger. |
| Sanofi share/legal original | French publicly traded SA. Current share/vote charts do not close full beneficial investors here. | France; registered 46 Avenue de la Grande Armée, Paris. | Tier 4; seller identity | D. August 2026 table; selected legal body read, chart-image ownership unverified. |
| Sanofi headquarters original | Own commercial-company statement; no page-level financial attribution. | France; 46–48 Avenue de la Grande Armée, Paris. | Tier 4; seller identity | D. November 2022 announcement; current registration separately corroborates Paris. Not pack-factory evidence. |
| Milpharm filed controller | Agile Pharma BV, Amsterdam, Netherlands declared at least 75% share control. Full beneficial investor chain unclosed. | United Kingdom company; Dutch controller. | Tier 3; filed record, provisional | B. April 2016 notification; registry does not check filing accuracy. |
| Milpharm filing history | March 2026 accounts filed June 19, 2026; linked accounts retrieval failed. | United Kingdom company. | Tier 3; filed record, provisional | B. Index read, full company accounts not read; no complete audit claim. |
| Aurobindo control statement | July 2025 Pharmacin merger into Agile Pharma; both stated wholly owned step-down subsidiaries. | India; Hyderabad corporate address. | Tier 4; seller filing | D. Actual two-page own statement; not complete ultimate-investor or pack-plant proof. |
| Aurobindo interim finance | Pharmaceutical sales/other operating and investment income; Milpharm UK/Agile Netherlands listed step-down subsidiaries. Exact product allocation unclosed. | India; Galaxy, Hyderabad Knowledge City, Raidurg Panmaktha. | Tier 4; seller finance | D. November 2025 14-page own interim report, selected statements/list read; limited review, not full audit. |
| BMS Form 10-K, 2025 | Public shareholders; medicine development/licensing/manufacture/marketing revenues. Historic CURE and personal allocations unclosed. | United States; Delaware; Princeton, New Jersey principal office. | Tier 4; sponsor finance | D. February 2026 filing, selected business/financial body read. Current report does not establish old payments. |
| NINDS budget justification | FY 2026 enacted distinct from FY 2027 request; public grants/contracts/intramural programmes and partnership route. Exact POINT allocation unclosed. | United States NIH institute. | Tier 3; own fiscal record | B provisional. Actual 22-page selected fiscal body read; gifts/partner payments not cleared. |
| NINDS contact original | Public institute contact; not a financial ledger. | United States; Bethesda mailing location. | Tier 3; own identity record | B provisional. Indexed original contact body; direct fetch failed. Exact physical headquarters unverified. |
| CIHR June 2026 quarter | Parliamentary appropriations/statutory spending. Exact historical investigator-award allocation unclosed. | Canada federal agency. | Tier 3; own fiscal record | B provisional. Indexed full original financial body/annexes read; unaudited/unreviewed quarter, direct access failed. |
| CIHR partnership original | Public/private/charitable partner co-funding route; full donor ledger and old award payments unclosed. | Canada; 234 Laurier Avenue West, Ottawa. | Tier 3; own financial statement | B provisional. November 2023 body; no partner assigned to a CURE award. |
| Heart & Stroke accounts, 2025 | Donations, corporate sponsorship, lottery, government project grants and investments/other income. Old Ontario chair/Canadian fellowship allocation unclosed. | Canada; national foundation. | Tier 3; own fiscal report | B provisional. Actual 23-page audited original selected income notes read; charity status does not clear old trials. |
| Heart & Stroke contact | Own donation service and contact; not a full donor or historic Ontario-entity ledger. | Canada; 2300 Yonge Street, Toronto, Ontario. | Tier 3; own identity record | B provisional. Current own footer read; historic funding entity remains distinct. |
| AstraZeneca finance, 2025 | Product sales, alliance/royalty and collaboration revenues; public shareholder finance. Historic named POINT grant payments unclosed. | United Kingdom group; legal location below. | Tier 4; commercial backer | D. Actual 79-page financial extract, selected accounting body read; no independent efficacy inference. |
| AstraZeneca legal original | England/Wales public limited company; not a complete beneficial-owner ledger. | United Kingdom; 1 Francis Crick Avenue, Cambridge. | Tier 4; own identity | D. Actual legal body read; registered office not every factory or historic payment. |
| Boehringer own 2025 report | Family-owned human/animal pharmaceutical business. Complete current audited ledger and old personal consulting payments unclosed. | Germany; historical own imprint identifies Ingelheim, current physical address unclosed. | Tier 4; commercial backer | D. Indexed full own summary read; direct body blank. No full current financial-PDF claim. |
| SanBio company original | Listed Japanese parent; develops/produces/sells regenerative medicines. Full audited revenue/investor ledger and historic grant allocation unclosed. | Japan: Tokyo parent; US SanBio Inc: Oakland, California. | Tier 4; commercial backer | D. Actual current group/business body read; parent/subsidiary distinguished. |
| J&J Neuravi acquisition, 2017 | April 2017 completed Neuravi acquisition stated; no individual POINT payment established. | United States group; acquired Irish device business. | Tier 4; seller statement | D. Actual dated own acquisition passage read; not current whole-group ownership proof alone. |
| J&J current entity notice | Current MedTech notice lists Neuravi Ltd; no individual study payment identified. | Ireland; Block 3, Ballybrit Business Park, Galway. | Tier 4; seller identity | D. May 2026 policy entity list read; not manufacturing or complete finance proof. |
| J&J own 2025 results | Public shareholder group; medicine/device customer sales. Historic Neuravi personal-fee allocation unclosed. | United States; New Brunswick, New Jersey. | Tier 4; commercial finance | D. January 2026 own results; selected unaudited schedules, not full financial audit. |
| ConcePTION project finances | IMI2 821520 EU/EFPIA contributions; manufacturer participants include Sanofi/BMS; BioNotus EU award listed. Exact milk-study allocation unclosed. | EU project; Utrecht coordination; international participants. | Tier 3; mixed finance record | C provisional. Actual contribution/participant table read; programme totals do not establish each study payment. |
| IHI funding model | EU/industry partnership; IMI/IMI2 managed too. Industry primarily contributes resources in kind, sometimes cash; declarations audited. | European Union body; location below. | Tier 3; own mixed-funding record | C provisional. Actual model read; current IHI rules not automatically historical IMI grant terms. |
| IHI contact original | Own public/private-programme contact, not a financial ledger. | Belgium; Brussels, Avenue de la Toison d’Or 56–60. | Tier 3; own identity record | B provisional. Indexed complete contact body read; direct fetch failed. |
| EFPIA membership original | Pharmaceutical-company/national-industry association membership. Full audited fees/revenue and study allocations unclosed. | European trade association; Brussels office below. | Tier 3; own industry-body record | C provisional. Membership body read; no blanket independence from member companies. |
| EFPIA contact original | Own trade-body contact; no complete financial ledger. | Belgium; Neo Building, Rue Montoyer 51, Brussels. | Tier 3; own identity record | B provisional. Actual contact body read; office does not assign author fees. |
| FWO annual finance, 2025 | Mainly Flemish government; federal/EU finance, companies/funds, legacies and financial income also reported. Exact cited fellowship allocations unclosed. | Belgium public-utility foundation. | Tier 3; own mixed-funding report | B provisional. Actual 101-page original selected income/financial overview read, not every donor receipt. |
| FWO governance/contact | Government-managed research allocation; gifts/legacies/prizes within associated governance. No exact study payment identified. | Belgium; HOEK 38, Leuvenseweg 38, Brussels. | Tier 3; own institution record | B provisional. Actual governance/contact body read; not whole donor-interest clearance. |
| BioNotus own company original | Founder Annaert; commercial bioanalysis, modelling and ADMET services. Complete audited revenue/investors/customer ledger unclosed. | Belgium; Galileilaan 15, Niel. | Tier 4; commercial service source | D. Actual own team/business/contact body, update date unclosed. No personal current-study fee inferred. |
| eMC publisher original | Datapharm Ltd owns eMC; pharmaceutical companies pay subscriptions to publish approved manufacturer/regulator material. Exact product fee and complete investors/revenues unclosed. | United Kingdom; Cassini Court, Randalls Way, Leatherhead, Surrey. | Tier 4; commercial publishing source | D. Own full publishing/finance/contact body read; hosting does not clear trial interests. |
| England PCA, 2025/26 | Agency accounts. Exact programme/contributor allocation unclosed. | England community dispensing. | Tier 2; public statistics, provisional | B. Raw original row checked; items are not patients or benefits. |
| PCA methodology | Shared NHSBSA route below; exact allocation unclosed. | England dataset. | Tier 2; public definitions, provisional | B. June 2026; not worldwide popularity. |
| MHRA Yellow Card | Regulator finances. Exact service/contributor allocations unclosed. | United Kingdom. | Tier 3; regulatory/reporting context | B provisional. Suspected reports do not prove causation or incidence. |
| NHSBSA accounts, 2025/26 | DHSC Parliamentary funding plus operating service/contract income; student-support receipts separately treated. Exact PCA allocation not identified. | United Kingdom; Newcastle upon Tyne. | Tier 3; own financial report | B provisional. Statutory accounts; selected funding notes read. Institutional route only. |
| NHS content policy | DHSC-funded website; advertising/corporate sponsorship excluded by policy; contributor declarations required. | United Kingdom. | Tier 3; own policy | C provisional. October 2022; review overdue. Contributor register unclosed. |
| SPS service commissioning | NHS England commissioning with nine host trusts/subcontractors. Published arrangements run to 31 March 2026; renewal and individual provider money unclosed. | United Kingdom; distributed providers, no single HQ verified. | Tier 3; own service statement | B provisional. Contract disclosure; dated coverage does not clear each author/page. |
| NHS England accounts, 2025/26 | DHSC grant-in-aid principally; additional service, research and consolidated charge/other income. Parent and consolidated routes differ; SPS allocation unidentified. | United Kingdom; Leeds contact address. | Tier 3; own financial report | B provisional. Selected notes read; commissioner finances do not replace host-trust ledgers. |
| MHRA accounts, 2025/26 | DHSC grant-in-aid plus statutory industry fees, customer/service income, research grants and biological-standard sales. | United Kingdom; London/Canary Wharf and South Mimms sites. | Tier 3; own financial report | B provisional. Selected current income notes read; exact safety-alert allocation unclosed. |
| NLM FY 2027 justification | FY 2026 enacted funding distinguished from FY 2027 request. Institutional grants/contracts/intramural routes; DailyMed allocation and individual gifts unclosed. | United States; Bethesda NIH library. | Tier 3; own budget report | B provisional. Selected actual budget table read; public hosting does not make labels independent. |
| NLM appropriations index | Congressional justification index; 2026 consolidation described as a proposal. Current 2027 original separately read above. | United States; 8600 Rockville Pike, Bethesda. | Tier 3; own institution record | B provisional. Location/index only; no completed restructuring inferred. |
| NIH gift-administration policy | Conditional/unconditional gift authority with conflict checks; supplementary routes include authorised foundation transfers. Authority does not establish a named NLM donation. | United States; NIH-wide policy. | Tier 3; own financial policy | B provisional. Actual policy read; donor receipts and exact medicine-page allocations unclosed. |
Frequently asked questions
Can I stop for dental work? Only on professional instructions; tell the dentist. Procedure advice.
Can I add aspirin for pain? Only with medical agreement. Pain advice.
Does the new milk study prove safety? No: two older, partially breastfed infants cannot settle newborn or long-term safety. Original scope.
Have I taken too many Plavix tablets? Contact a doctor or the nearest hospital emergency department. Leaflet instruction.
Sources and funding notes
Plavix leaflet text is December 2022.
SPS’s earlier no-published-data statement is superseded; full bibliography unretrieved.
POINT methods/full published Notes were read via a legitimate replica/indexed original; direct publisher access failed.
Full milk-case methods/funding/COI read; programme support and separate registry interest do not establish personal current-study fees.
Complete historical payments, beneficial investors, donor receipts and source-page allocations remain unclosed.
Follow professional advice and local product instructions; omissions do not establish safety.
- NHS purpose — Uses and brand aliases
- NHS side effects — Urgent routes
- NHS taking — Continuity and excess dose
- NHS pregnancy/feeding — Individual clinical decisions
- NHS combinations — Medicine and supplement checks
- NHS suitability — Pre-treatment history
- NHS questions — Procedures, juice and lifestyle
- Plavix UK SmPC — UK licence/safety
- Plavix PIL — Patient warnings
- Milpharm SmPC — Generic warnings
- US Plavix — Licence/warnings
- SPS antiplatelets and feeding — Dated professional feeding framework
- CURE original, 2001 — Trial methods and money
- POINT original, 2018 — Trial methods and disclosures
- 2025 milk cases — Observational limits
- Sanofi H1 finance, 2026 — Current seller revenue
- Sanofi share/legal original — Legal and investor limits
- Sanofi headquarters original — Dated headquarters
- Milpharm filed controller — Immediate declared control
- Milpharm filing history — Financial access gap
- Aurobindo control statement — Declared intermediate group link
- Aurobindo interim finance — Generic group revenue and link
- BMS Form 10-K, 2025 — Historical sponsor current business
- NINDS budget justification — Public trial backer finance
- NINDS contact original — Backer location
- CIHR June 2026 quarter — CURE academic backer finance
- CIHR partnership original — Other funding routes and location
- Heart & Stroke accounts, 2025 — Charitable backer revenue
- Heart & Stroke contact — National backer location
- AstraZeneca finance, 2025 — Author-interest counterparty finance
- AstraZeneca legal original — Backer legal jurisdiction
- Boehringer own 2025 report — Author-interest business/access limits
- SanBio company original — Named author-grant counterparty
- J&J Neuravi acquisition, 2017 — Historic group relationship
- J&J current entity notice — Current named counterparty location
- J&J own 2025 results — Counterparty group revenue
- ConcePTION project finances — Industry/public programme route
- IHI funding model — Cash/resource distinction
- IHI contact original — Programme office jurisdiction
- EFPIA membership original — Industry representative identity
- EFPIA contact original — Industry-body office
- FWO annual finance, 2025 — Other milk-study backer revenue
- FWO governance/contact — Backer location and gift route
- BioNotus own company original — Declared author business interest
- eMC publisher original — Label publisher revenue
- England PCA, 2025/26 — Prescribing context
- PCA methodology — Counting limits
- MHRA Yellow Card — Reporting boundary
- NHSBSA accounts, 2025/26 — Institutional finance
- NHS content policy — Website funding policy
- SPS service commissioning — Programme financial route
- NHS England accounts, 2025/26 — Commissioner finance
- MHRA accounts, 2025/26 — Safety regulator finance
- NLM FY 2027 justification — Label-host institution finance
- NLM appropriations index — Host location and budget provenance
- NIH gift-administration policy — Gift authority, not receipt
Educational research reviewed 5 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.